Viralgen Vector Core and Elpida Therapeutics partner to : vi

Trial participants with Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) could benefit from this joint effort to manufacture...

Related Keywords

United States , London , City Of , United Kingdom , Gipuzkoa , Pais Vasco , Spain , America , Spanish , Terry Pirovolakis , R Jude Samulski , Josh Grieger , Technology Park , London Stock Exchange , Bayer Ag , Contract Development , University Of North Carolina , Manufacturing Organization , Spanish Agency For Medicines , Vector Core , Elpida Therapeutics , North America , Current Good Manufacturing Practice , Chief Technical Officer Josh Grieger , Gipuzkoa Science , Scientific Park , Spanish Agency , Medical Devices , London Stock , Viralgen Vector Core ,